DEINOVE (Euronext Growth Paris: ALDEI), a French biotechnology company pioneering the study and exploitation of bacterial biodiversity to address the urgent and global challenge of antimicrobial resistance, announces that at the company’s request (press release published October 28, 2022). the Commercial Court of Montpellier decided on November 7, 2022 to open receivership proceedings with a observation period of 6 weeks from the opening judgment, during which operations will continue.

The court also appointed SELARL FHBX, in the person of Maître Jean-François Blanc, as court administrator.

« We examine all solutions in cooperation with the court-appointed receiver.possible recovery options says Alexis Rideau, CEO of DEINOVE.

The purpose of this procedure is to evaluate all the solutions that allow, under the best conditions, to continue the activity, maintain employment and settle the debts, as well as to start a process of looking for investors as part of a recovery plan continuation or a divestment plan.

Press releases are published regularly on the progress of the restructuring process.

The listing of the Company’s shares (ISIN: FR0010879056), suspended on October 28, 2022, will resume on November 8, 2022.

ABOUT DEINOVE

DEINOVE is a French biotechnology company pioneering in unlocking a 99.9% unexplored area of ??life: “microbial dark matter”. By uncovering the metabolic potential of rare or previously considered uncultivable bacteria, it addresses a global health and economic challenge: resistance to…